TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Korro Bio ( (KRRO) ) just unveiled an announcement.
On November 11, 2025, Korro Bio and Novo Nordisk agreed to pause their research collaboration and license agreement for 12 months, allowing Korro to wind down its activities during this period with Novo Nordisk reimbursing certain costs. This strategic move is part of Korro’s broader restructuring efforts, which include a 34% workforce reduction to extend its cash runway into the second half of 2027. Additionally, Korro announced the resignation of its Chief Medical Officer, Dr. Olukemi A. Olugemo, effective November 12, 2025, who will continue as an advisor for three months post-resignation. These changes are aimed at refocusing resources on advancing Korro’s RNA editing platform and GalNAc-conjugated programs targeting liver diseases.
The most recent analyst rating on (KRRO) stock is a Buy with a $93.00 price target. To see the full list of analyst forecasts on Korro Bio stock, see the KRRO Stock Forecast page.
Spark’s Take on KRRO Stock
According to Spark, TipRanks’ AI Analyst, KRRO is a Neutral.
Korro Bio’s stock score reflects its current position as a developmental biotech firm. Financial performance is the most significant factor, showing the challenges of high R&D costs and reliance on external funding. The technical analysis suggests short-term downward pressure, while valuation is impacted by its negative earnings and lack of dividends. The company needs to focus on operational efficiency and revenue growth to improve its stock performance.
To see Spark’s full report on KRRO stock, click here.
More about Korro Bio
Korro Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on RNA editing for both rare and highly prevalent diseases.
Average Trading Volume: 228,163
Technical Sentiment Signal: Hold
Current Market Cap: $306.3M
For detailed information about KRRO stock, go to TipRanks’ Stock Analysis page.